#Amylyx Pharmaceuticals (AMLX)

Amylyx Pharma Informed European CHMP is Trending Toward a Negative Opinion for Conditional Marketing Authorization of AMX0035 for ALS

Amylyx Pharmaceuticals Amylyx Pharmaceuticals ( AMLX ) announced an update on the ongoing review of its Marketing Authorization Application ( MAA ) for AMX0035 (taurursodiol]) regarding the treatment...

P

Prohost Biotech

May 30, 2023

Promising Stocks in the First Two Trading Days of 2023

The Stock Market in the New Year It is still too early to tell how the stock market will perform in 2023. However, o n Tuesday January 3, 2023 (the first market trading day in 2023), most biotech stoc...

P

Prohost Biotech

Jan 4, 2023

Gilead Sciences - Still Way Undervalued

Prohost Letter #453 Gilead Sciences Still Way UNDERVALUED Finally, many analysts who happened to downgrade Gilead Science’s ( GILD ) stock for years are upgrading it. Demonstrating time and time again...

P

Prohost Biotech

Dec 29, 2022

Acumen Pharmaceuticals: New Effort to Treat Alzheimer’s Disease Granted FDA Fast Track Designation

Acumen Pharmaceuticals Product ACU193 On October 23, 2022, Acumen Pharmaceuticals ( ABOS ) announced that the first clinical-stage monoclonal antibody ACU193 - an anti-amyloid beta oligomer antibody,...

P

Prohost Biotech

Oct 25, 2022

Treating Untreatable Disease - NASH

Prohost Letter #452 Treating Untreatable Disease - NASH Non Alcoholic Steatohepatitis The efforts spent on treating Non Alcoholic Steatohepatitis (NASH) have reached a promising stage where clinical...

P

Prohost Biotech

Oct 13, 2022

Amylyx Pharmaceuticals Announces FDA Approval of RELYVRIO™ for of ALS Leading to a Weird Stock Market Reception

Amylyx Pharmaceuticals in the NEWS Amylyx Pharmaceuticals ( AMLX ) announced that the U.S. FDA has approved RELYVRIO™ (sodium phenylbutyrate and taurursodiol) for the treatment of adults with amyotrop...

P

Prohost Biotech

Sep 30, 2022

Amylyx Pharmaceuticals Announces FDA Advisory Committee Supports Approval of AMX0035 for ALS

Amylyx Pharmaceuticals in the News Amylyx Pharmaceuticals ( AMLX ) : The U.S. FDA Peripheral and Central Nervous System Drugs Advisory Committee has voted (7 yes votes and 2 no votes) that the availab...

P

Prohost Biotech

Sep 8, 2022

The FDA Advisory Committee Will Soon Review the NDA of Amylyx Pharmaceuticals' Product AMX0035 for ALS

On September 7th the FDA Will Review Amylyx Pharmaceuticals NDA for ALS Treatment Amylyx Pharmaceuticals ( AMLX ) announced that the U.S. FDA Peripheral and Central Nervous System Advisory Committee (...

P

Prohost Biotech

Aug 11, 2022

Health Canada Approved Amylyx Pharmaceuticals' Product ALBRIOZA for Amyotrophic Lateral Sclerosis

The Great News from Amylyx Pharmaceuticals On Jun. 13, 2022, Amylyx Pharmaceuticals ( AMLX ) announced that Health Canada has approved ALBRIOZA (sodium phenylbutyrate and ursodoxicoltaurine), with con...

P

Prohost Biotech

Jun 23, 2022

1m

4

News & Comments

Amylyx Pharmaceuticals: Continuing to Offer Promising Results in Treating ALS

Amylyx Pharmaceuticals Updated Plans to Advance AMX0035 Amylyx Pharmaceuticals, Inc. provided an update on its plans to advance AMX0035 through the clinical development process for the treatment of am...

P

Prohost Biotech

Apr 20, 2021

The Whole World Against the Blind SARS-CoV-2 Virus

Prohost Letter 442 The Whole World Against the Blind SARS-CoV-2 Virus Investors have no doubt profited from the developers of COVID-19 vaccines which include: Moderna ( MRNA ), Novavax ( NVAX ) and Bi...

P

Prohost Biotech

Sep 28, 2020

1m

3

News & Comments

Amylyx Pharmaceuticals: Clinical Trial Results Demonstrate Statistically Significant Treatment Benefit in Lou Gehrig's Disease Patients

Amylyx Pharmaceuticals With the advancement of biological sciences, and increased information about the pathways of diseases, we are getting more interested in biotech firms that are focused on treati...

P

Prohost Biotech

Dec 17, 2019

6m

0